Search Results - Stuart H. Isaacson

  • Showing 1 - 18 results of 18
Refine Results
  1. 1

    Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease by Bruno Bergmans, Veronica Clark, Stuart H. Isaacson, Tobias Bäumer

    Published in Clinical Parkinsonism & Related Disorders (2023-01-01)
    Get full text
    Article


  2. 2

    Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9... by Bruno Bergmans, Veronica Clark, Stuart H. Isaacson, Tobias Bäumer

    Published in Clinical Parkinsonism & Related Disorders (2024-01-01)
    Get full text
    Article


  3. 3

    Ondansetron for the treatment of Parkinson’s disease psychosis: Rationale and literature review by Jaslovleen Kaur, Abhishek Lenka, Jonathan R Isaacson, Stuart H Isaacson

    Published in Annals of Movement Disorders (2023-01-01)
    Get full text
    Article


  4. 4

    Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? by Stuart H. Isaacson, Fernando L. Pagan, Mark F. Lew, Rajesh Pahwa

    Published in Clinical Parkinsonism & Related Disorders (2022-01-01)
    Get full text
    Article


  5. 5

    Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis by Stuart H. Isaacson, Rajesh Pahwa, Fernando Pagan, Victor Abler, Daniel Truong

    Published in Clinical Parkinsonism & Related Disorders (2024-01-01)
    Get full text
    Article


  6. 6

    Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment by Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri

    Published in Clinical Parkinsonism & Related Disorders (2023-01-01)
    Get full text
    Article


  7. 7

    How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature by Stuart H. Isaacson, Richard B. Dewey, Jr., Rajesh Pahwa, Daniel E. Kremens

    Published in Clinical Parkinsonism & Related Disorders (2023-01-01)
    Get full text
    Article


  8. 8

    Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel by Rajesh Pahwa, Stuart H. Isaacson, Gary W. Small, Yasar Torres-Yaghi, Fernando Pagan, Marwan Sabbagh

    Published in Neurology and Therapy (2022-07-01)
    Get full text
    Article


  9. 9

    Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel by Rajesh Pahwa, Stuart H. Isaacson, Gary W. Small, Yasar Torres-Yaghi, Fernando Pagan, Marwan Sabbagh

    Published in Neurology and Therapy (2023-07-01)
    Get full text
    Article


  10. 10

    Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? by Robert A. Hauser, William G. Ondo, Yi Zhang, Alyssa Bowling, Bradford Navia, Eric Pappert, Stuart H. Isaacson

    Published in Journal of Parkinson’s Disease (2023-05-01)
    Get full text
    Article


  11. 11

    Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease by K. Ray Chaudhuri, Manon Bouchard, Eric Freire-Alvarez, Rajesh Pahwa, Lars Bergmann, Resmi Gupta, Pavnit Kukreja, Megha B. Shah, Stuart H. Isaacson

    Published in Clinical Parkinsonism & Related Disorders (2025-01-01)
    Get full text
    Article


  12. 12

    Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel by Stuart H. Isaacson, Richard Dewey, Robert A. Hauser, Daniel Kremens, Rajeev Kumar, Mark Lew, William Ondo, Fernando Pagan, Kelly E. Lyons, Rajesh Pahwa

    Published in Clinical Parkinsonism & Related Disorders (2024-01-01)
    Get full text
    Article


  13. 13

    AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions by Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek

    Published in Clinical Parkinsonism & Related Disorders (2021-01-01)
    Get full text
    Article


  14. 14

    Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study by Stuart H Isaacson, Alberto J Espay, Rajesh Pahwa, Pinky Agarwal, Holly A Shill, Jennifer Hui, Khashayar Dashtipour, Mark Lew, Peibing Qin, Andrea E Formella, Gianpiera Ceresoli-Borroni, Peter A LeWitt

    Published in Journal of Parkinson’s Disease (2025-03-01)
    Get full text
    Article


  15. 15

    Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial by Rajesh Pahwa, Eric Molho, Mark Lew, Khashayar Dashtipour, Ramon A. Gil, Fredy J. Revilla, Thomas Clinch, Peibing Qin, Stuart H. Isaacson, on behalf of the OPen Label Trial of Intraglandular MYobloc injections for Sialorrhea Treatment (OPTIMYST) study group

    Published in Neurology and Therapy (2025-06-01)
    Get full text
    Article


  16. 16

    Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a Mutation: Results from Part 1 of the Randomized, Double-Blinded, Place... by M. Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, Thomas Gasser, Stuart H. Isaacson, Sebastiaan J.M. Gaemers, Pascal Minini, Stéphane Saubadu, Jyoti Sharma, Samantha Walbillic, Roy N. Alcalay, Gary Cutter, Nobutaka Hattori, Günter U. Höglinger, Kenneth Marek, Anthony H.V. Schapira, Clemens R. Scherzer, Tanya Simuni, Nir Giladi, Sergio Pablo Sardi, Tanya Z. Fischer

    Published in Journal of Parkinson’s Disease (2022-02-01)
    Get full text
    Article


  17. 17

    Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia by Christopher H. Gibbons, Todd Levine, Charles H. Adler, Bailey Bellaire, Ningshan Wang, Pinky Agarwal, Georgina M. Aldridge, Alexandru Barboi, Daniel Claassen, Virgilio G. H. Evidente, Douglas Galasko, Alejandra Gonzalez‐Duarte, Ramon Gil, Mark Gudesblatt, Stuart H. Isaacson, Horacio Kaufmann, Pravin Khemani, Rajeev Kumar, Guillaume Lamotte, Andy J. Liu, Nikolaus R. McFarland, Mitchell G. Miglis, Adam Reynolds, Gregory A. Sahagian, Marie‐Helene Saint‐Hilaire, Julie B. Schwartzbard, Wolfgang Singer, Michael J. Soileau, Steven Vernino, Patricio Millar Vernetti, Oleg Yerstein, Roy Freeman

    Get full text
    Article


  18. 18

    LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort by Tatiana Usnich, Eva-Juliane Vollstedt, Nathalie Schell, Volha Skrahina, Xenia Bogdanovic, Hanaa Gaber, Toni M. Förster, Andreas Heuer, Natalia Koleva-Alazeh, Ilona Csoti, Ayse Nazli Basak, Sibel Ertan, Gencer Genc, Peter Bauer, Katja Lohmann, Anne Grünewald, Emma L. Schymanski, Joanne Trinh, Susen Schaake, Daniela Berg, Doreen Gruber, Stuart H. Isaacson, Andrea A. Kühn, Brit Mollenhauer, David J. Pedrosa, Kathrin Reetz, Esther M. Sammler, Enza Maria Valente, Franco Valzania, Jens Volkmann, Simone Zittel, Norbert Brüggemann, Norbert Brüggemann, Meike Kasten, Meike Kasten, Arndt Rolfs, Christine Klein, The LIPAD Study Group

    Published in Frontiers in Neurology (2021-08-01)
    Get full text
    Article


Search Tools: